We are live on ! Find out more
ACRV icon

Acrivon Therapeutics
ACRV

48 hedge funds and large institutions have $32.7M invested in Acrivon Therapeutics in 2025 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 11 increasing their positions, 19 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

54% more capital invested

Capital invested by funds: $21.2M → $32.7M (+$11.5M)

1.07% less ownership

Funds ownership: 56.78% → 55.71% (-1.1%)

9% less funds holding

Funds holding: 53 → 48 (-5)

42% less repeat investments, than reductions

Existing positions increased: 11 | Existing positions reduced: 19

45% less first-time investments, than exits

New positions opened: 6 | Existing positions closed: 11

Holders
48
Holders Change
-5
Holders Change %
-9.43%
% of All Funds
0.63%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
6
Increased
11
Reduced
19
Closed
11
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
UBS Group
UBS Group
Switzerland
+$960K
2
Two Sigma Investments
Two Sigma Investments
New York
+$194K
3
Renaissance Technologies
Renaissance Technologies
New York
+$160K
4
Two Sigma Advisers
Two Sigma Advisers
New York
+$146K
5
Acadian Asset Management
Acadian Asset Management
Massachusetts
+$129K

Top Sellers

Rank Fund Capital Flow
1
Citadel Advisors
Citadel Advisors
Florida
-$498K
2
Jacobs Levy Equity Management
Jacobs Levy Equity Management
New Jersey
-$455K
3
HF
HRT Financial
New York
-$173K
4
Goldman Sachs
Goldman Sachs
New York
-$169K
5
Millennium Management
Millennium Management
New York
-$156K
Name Holding Trade Value Shares
Change 		Change in
Stake
RCM
1
RA Capital Management
Massachusetts
$15.1M – – –
SCV
2
Sands Capital Ventures
Virginia
$3.84M – – –
Citadel Advisors
3
Citadel Advisors
Florida
$2.79M -$498K -354,193 -19%
Wellington Management Group
4
Wellington Management Group
Massachusetts
$1.61M – – –
UBS Group
5
UBS Group
Switzerland
$1.24M +$960K +682,763 +150,058%
Vanguard Group
6
Vanguard Group
Pennsylvania
$1.13M +$46.2K +32,901 +6%
Renaissance Technologies
7
Renaissance Technologies
New York
$1.13M +$160K +114,105 +22%
Focus Partners Wealth
8
Focus Partners Wealth
Massachusetts
$988K +$27.9K +19,846 New
ACA
9
Acorn Capital Advisors
New York
$733K – – –
BlackRock
10
BlackRock
New York
$599K -$108K -76,665 -19%
Two Sigma Investments
11
Two Sigma Investments
New York
$578K +$194K +138,033 +76%
Jane Street
12
Jane Street
New York
$524K -$31.7K -22,581 -7%
Geode Capital Management
13
Geode Capital Management
Massachusetts
$348K +$38.9K +27,671 +17%
Millennium Management
14
Millennium Management
New York
$335K -$156K -111,005 -37%
Marshall Wace
15
Marshall Wace
United Kingdom
$271K -$44.2K -31,472 -17%
Two Sigma Advisers
16
Two Sigma Advisers
New York
$247K +$146K +103,900 +319%
Squarepoint
17
Squarepoint
New York
$189K -$67.9K -48,281 -32%
Acadian Asset Management
18
Acadian Asset Management
Massachusetts
$165K +$129K +92,004 New
State Street
19
State Street
Massachusetts
$122K – – –
Morgan Stanley
20
Morgan Stanley
New York
$103K -$8.23K -5,856 -9%
AG
21
Algert Global
California
$81K +$62.8K +44,648 New
Northern Trust
22
Northern Trust
Illinois
$76.3K -$6.48K -4,610 -10%
BCM
23
Bluefin Capital Management
New York
$76.1K +$59.1K +42,039 New
XT
24
XTX Topco
Cayman Islands
$65.1K -$98.6K -70,164 -66%
BCM
25
Bridgeway Capital Management
Texas
$41.4K – – –
1
2 3

ACRV Hedge Fund Activity: Q3 2025 in Review

48 of the 7,621 institutional investors tracked by Wall St. Rank reported a position in Acrivon Therapeutics (ACRV) for Q3 2025, worth a combined $32.7M — up 54% from $21.2M a quarter earlier.

Sellers outnumbered buyers: 11 funds closed out of ACRV and 6 opened new positions — a net loss of 5 holders — while 19 trimmed existing stakes and 11 added.

The largest buyer was UBS Group, adding an estimated $960K. The largest seller was Citadel Advisors, cutting an estimated $498K.

  • 48 institutional investors held Acrivon Therapeutics (ACRV) as of Q3 2025, down from 53 in Q2 2025.
  • Funds reported $32.7M of Acrivon Therapeutics stock for Q3 2025, up 54% quarter-over-quarter.
  • 6 funds opened new Acrivon Therapeutics positions in Q3 2025 and 11 closed out, a net change of -5 holders.
  • The largest Acrivon Therapeutics buyer in Q3 2025 was UBS Group, an estimated $960K added.
  • The largest Acrivon Therapeutics seller in Q3 2025 was Citadel Advisors, an estimated $498K sold.

Based on aggregated 13F filings for Q3 2025.